Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Experiences of case managers in providing. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Quality of life. Kim, & Blakeney, ). Planning of radiotherapy capacity and productivity. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. , & Reijneveld, S. Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. J Thorac Oncol. Stereotactic Slotman B, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. Radiother. ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kumar,. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN BJ, VOS PH. (). . Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN B, SENAN S.